Third, although the patient in our report got 7 months of PFS in the fourth line treatment, the efficacy of bevacizumab plus pemetrexed for ALK-rearrangement NSCLC is still needed to be studied in future prospective trials. This evidence concerns the gene ALK and non-small cell lung carcinoma.